|By Marketwired .||
|July 29, 2014 02:00 AM EDT||
NEUCHATEL, SWITZERLAND -- (Marketwired) -- 07/29/14 -- Masimo (NASDAQ: MASI) today announced CE Mark and limited market release of Radius-7 for the Root® patient monitoring and connectivity platform, the first and only wearable, wireless monitor with Masimo's breakthrough rainbow® SET® technology, enabling early identification of clinical deterioration while offering patients continuous monitoring with freedom of movement.
With rainbow® SET® noninvasive measurements, Radius-7 with Root can alert clinicians -- at the bedside or remotely, through the Masimo Patient SafetyNet remote monitoring and notification system -- of critical changes in a patient's oxygen saturation, pulse rate, respiration rate, or haemoglobin that may indicate pulmonary, cardiac, or internal bleeding problems. Lightweight at only 155g (0.34 lbs), the Radius-7 attaches to the patient's arm or can be placed alongside the patient in their bed, allowing untethered monitoring while they are in bed or out. With no need to disconnect and reconnect the cable to get out of bed, the Radius-7 reduces the need for nursing assistance. And the Radius-7's wireless communication functionality -- either short-range via Bluetooth back to Root or with upgradeable WiFi for long-range communication* -- ensures the patient can be continuously monitored and connected to caregivers wherever they are in the hospital.
Studies have shown that patient mobility is a key factor in more rapid patient recovery.(1) Radius-7 allows clinicians to mobilize their patients.
"With this new technology we have made another important step to improve patient safety," said Caroline Stade, chief nursing officer at University Children's Hospital Basel (UKBB) in Basel, Switzerland. "Children can be cared for and move about as they are able, while remaining under seamless, clinical surveillance. This makes parents, and of course, nurses and clinicians, feel better about the quality of care offered to our pediatric patients."
"In the past, wearable patient monitoring offered only limited measurements that were often plagued by false alarms. Radius-7 allows untethered clinically relevant patient monitoring," said Masimo founder and CEO Joe Kiani. "We expect Radius-7 and Root to change how hospitals think about monitoring, ushering in a new level of patient safety."
Radius-7 is not available for sale in the United States.
*The configuration for long-range communication is pending CE marking.
1 Needham D, Korupolu R, Zanni J, Pradhan P, Colantuoni E, Palmer J, Brower R, Fan E. "Early Physical Medicine and Rehabilitation for Patients With Acute Respiratory Failure: A Quality Improvement Project." Archives of Physical Medicine and Rehabilitation Vol 91, Issue 4, PP 536-542, April 2010
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa). Masimo SET® and Masimo rainbow® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our assumptions regarding timing of regulatory clearances and commercial availability in other countries; risks related to our assumptions that Radius-7 enables early identification of clinical deterioration with unprecedented patient ambulation and independence; reduces the need for nursing assistance; and allows for greater continuous monitoring for improved patient safety for all patients; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2645694
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2645696
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2645699
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2645701
Rapid innovation, changing business landscapes, and new IT demands force businesses to make changes quickly. In the eyes of many, containers are at the brink of becoming a pervasive technology in enterprise IT to accelerate application delivery. In this presentation, attendees learned about the: The transformation of IT to a DevOps, microservices, and container-based architecture What are containers and how DevOps practices can operate in a container-based environment A demonstration of how ...
Dec. 6, 2016 11:30 AM EST Reads: 1,010
Cloud Expo, Inc. has announced today that Andi Mann returns to 'DevOps at Cloud Expo 2017' as Conference Chair The @DevOpsSummit at Cloud Expo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great t...
Dec. 6, 2016 11:28 AM EST
Dec. 6, 2016 11:15 AM EST Reads: 355
Dec. 6, 2016 11:00 AM EST Reads: 541
Dec. 6, 2016 10:59 AM EST Reads: 120
Dec. 6, 2016 10:30 AM EST Reads: 954
Dec. 6, 2016 10:30 AM EST Reads: 1,152
Dec. 6, 2016 10:15 AM EST Reads: 532
Dec. 6, 2016 09:15 AM EST Reads: 2,141
Dec. 6, 2016 09:00 AM EST Reads: 3,966
Dec. 6, 2016 09:00 AM EST Reads: 5,810
Dec. 6, 2016 09:00 AM EST Reads: 707
Dec. 6, 2016 08:45 AM EST Reads: 7,125
Dec. 6, 2016 08:30 AM EST Reads: 1,336
Dec. 6, 2016 08:30 AM EST Reads: 882